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IMPLEMENTATION AND OPERATIONAL RESEARCH: EPIDEMIOLOGY AND PREVENTION
Reduction in Early Mortality on Antiretroviral Therapy for
Adults in Rural South Africa Since Change in CD4+ Cell
Count Eligibility Criteria
Richard J. Lessells, MBChB,*† Portia C. Mutevedzi, MSc,*‡ Collins C. Iwuji, MBBS, MSc,*§
and Marie-Louise Newell, MB, MSc, PhD*k
Objective: To explore the impact of expanded eligibility criteria for
antiretroviral therapy (ART) on median CD4+ cell count at ART
initiation and early mortality on ART.
Methods: Analyses included all adults ($16 years) initiated on
ﬁrst-line ART between August 2004 and July 2012. CD4+ cell count
threshold 350 cells per microliter for all adults was implemented in
August 2011. Early mortality was deﬁned as any death within 91
days of ART initiation. Trends in baseline CD4+ cell count and early
mortality were examined by year (August to July) of ART initiation.
Competing risks analysis was used to examine early mortality.
Results: A total of 19,080 adults (67.6% female) initiated ART.
Median CD4+ cell count at ART initiation was 110–120 cells per
microliter over the ﬁrst 6 years, increasing marginally to 145 cells
per microliter in 2010–2011 and more signiﬁcantly to 199 cells per
microliter in 2011–2012. Overall, there were 875 deaths within 91
days of ART initiation; early mortality rate was 19.4 per 100 person-
years [95% conﬁdence interval (CI) 18.2 to 20.7]. After adjustment
for sex, age, baseline CD4+ cell count, and concurrent tuberculosis
(TB), there was a 46% decrease in early mortality for those who
initiated ART in 2011–2012 compared with the reference period
2008–2009 (subhazard ratio, 0.54; 95% CI: 0.41 to 0.71).
Conclusions: Since the expansion of eligibility criteria, there is
evidence of earlier access to ART and a signiﬁcant reduction in early
mortality rate in this primary health care programme. These ﬁndings
provide strong support for national ART policies and highlight the
importance of earlier ART initiation for achieving reductions in
HIV-related mortality.
Key Words: HIV-1, antiretroviral agents, CD4 lymphocyte count,
mortality, access to health care
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INTRODUCTION
Rapid scale-up of public health antiretroviral therapy
(ART) programmes in the past decade has led to over 8 million
HIV-infected individuals receiving treatment in low- and
middle-income countries.1 One of the persistent challenges in
sub-Saharan Africa has been the high rate of early mortality on
ART, observed consistently in programmes from the region,
and reported to be substantially higher than in high-income
settings.2–5 There is strong evidence that mortality can be
reduced with earlier initiation of ART6,7; in 2010, the World
Health Organization (WHO) changed the recommended CD4+
cell count threshold for initiation of ART from 200 to 350 cells
per microliter.8 This recommendation has now been adopted by
several countries, including South Africa, the country with the
largest HIV treatment programme in the world.9
There is as yet limited evidence that adoption of these
policies has led to changes in the timing of presentation for care
and treatment or to early mortality on ART: one study from
Lesotho demonstrated that earlier initiation (CD4+ cell count
.200 cells per microliter compared with ,200 cells per micro-
liter) was feasible and associated with lower mortality in a routine
programmatic setting.10 Here, our main objective was to use data
from a large rural HIV treatment programme, where care is
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decentralized to primary health care level, to assess trends in
CD4+ cell count at initiation of ART, and mortality in the
ﬁrst three months after ART initiation. In particular, we set
out to test the hypothesis that early mortality would decline
after the expansion of treatment eligibility criteria in 2011.
The manuscript was prepared with reference to the Strength-
ening the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) statement.11,12
METHODS
The Hlabisa HIV Treatment and
Care Programme
The Hlabisa HIV Treatment and Care Programme
provides comprehensive HIV services at 17 primary health
care clinics and 1 district hospital in the predominantly rural
Hlabisa subdistrict (1430 km2) in northern KwaZulu-Natal.4,13
The programme is coordinated by the local Department of
Health with support from the Africa Centre for Health and
Population Studies (www.africacentre.ac.za). HIV treatment
and care are delivered largely by nurses and counselors in
adherence with national antiretroviral treatment guidelines.
South Africa implemented policy recommendations regarding
ART eligibility in a phased manner: between August 2004 and
April 2010, eligibility for adults was based on CD4+ cell count
,200 cells per microliter14; this was expanded initially in April
2010 to 350 cells per microliter for pregnant women and
individuals with active tuberculosis (TB) disease15; in August
2011, this was extended to 350 cells per microliter for all.9
ART was also recommended throughout for all individuals
with WHO clinical stage 4 and since April 2010 for all
individuals with drug-resistant TB.
Data Collection
Clinical information is collected at time of ART
initiation for all individuals and transferred from standardized
paper-based clinic records to a Microsoft SQL database
(Microsoft, Redmond, WA) housed at the Africa Centre.
Paper-based records are used at each clinic to capture
subsequent visits during follow-up on ART and to document
any change in vital status [death, loss to follow-up (LTF),
transfer out]. Information from these records is transferred to
the database at the end of each month. As part of routine
programme operations, a single tracking team attempts to
contact individuals who have missed clinic visits and thus
identiﬁes deaths in those lost to follow-up. To further improve
data on mortality for those lost to follow-up, mortality data
from the district hospital information system (recording in-
hospital deaths since January 2011) are imported to the
programme database periodically. Furthermore, mortality data
from the Africa Centre Demographic Surveillance System are
also used periodically to update vital status for individuals lost
to follow-up (approximately 40% of adults enrolled in the
treatment programme are members of the surveillance sys-
tem).13,16 With both these systems, individual records are linked
between databases after a standardized protocol using the South
African identity number, name, surname, age, and sex.
All CD4+ cell counts were performed by the National
Health Laboratory Service using the Beckman Coulter EPICS
XL ﬂow cytometer (Beckman Coulter Inc., Brea, CA). Since
January 2007, all CD4+ cell count results from the subdistrict
were provided by the National Health Laboratory Service and
were transferred to the programme database on a fortnightly
basis; laboratory records were merged with existing clinical
records after a standardized protocol using the unique South
African identity number, name, and date of birth. For indi-
viduals not yet commenced on ART, the database holds only
CD4+ cell count results but no clinical information.17
Data Analysis
All adults ($16 years) initiated on ﬁrst-line ART
between August 2004 and July 2012 and with a baseline
CD4+ cell count were included in the main analysis, unless
they had transferred into the programme already on ART (as
for this group, CD4+ cell count at initiation was not known).
Baseline CD4+ cell count was deﬁned as the last measured
CD4+ cell count up to 180 days before the date of ART initi-
ation. Individuals were divided into 8 groups on the basis of the
date of ART initiation (12-month period from August to July).
This categorization was chosen to allow clear delineation
before and after the change in CD4+ cell count threshold to
350 cells per microliter for all (August 2011). Baseline CD4+
cell counts were described with summary statistics: median,
interquartile range (IQR), and proportions in predeﬁned cate-
gories (,50, 50–200, 201–350, and.350 cells per microliter).
Trends in baseline CD4+ cell count were examined for all
adults and then for separate groups (males, pregnant females,
and nonpregnant females). To explore temporal changes in
timing of ﬁrst presentation for care since 2007, the ﬁrst re-
corded CD4+ cell count was used for all adults ($16 years
at test date). This was deﬁned as the earliest recorded CD4+
cell count in the database, providing the test date was before
the ART initiation date. Again these were summarized within
groups based on the test date (12-month period from August to
July starting in August 2007).
Early mortality was deﬁned for this analysis as deaths
within 3 months (#91 days) of ART initiation, a period pre-
viously reported to be responsible for approximately 60% of
the deaths in the ﬁrst year of ART in this programme.18 LTF
was deﬁned as .90 days without a recorded clinic visit; trans-
fer out was deﬁned as formal transfer out of the programme
(this did not include transfer between 2 clinics within the pro-
gramme). Analysis allowed for at least 3 months follow-up for
all individuals and a further 3 months before database closure
(January 13, 2013) to allow capture of deaths and LTF that
occurred during the ﬁrst 3 months and to minimize bias. Com-
peting risks analysis was used to generate cumulative incidence
functions for mortality.19 Follow-up time was censored at the
date of last clinic visit for those who transferred out or were
lost to follow-up. Analyses were also performed separately for
males, nonpregnant females, and pregnant females. Competing
risks regression was used to explore factors associated with
early mortality.20 Missing data for any categorical variable
were included in the model as a separate category.
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Sensitivity analyses were conducted to explore the
pattern of early mortality according to CD4+ cell count: early
mortality rates were estimated by time period, restricted to
those with CD4+ cell count ,50, #200, and .200 cells per
microliter. Sensitivity analyses were also conducted under the
assumption that either 20% or 40% of those individuals lost to
follow-up in the last time period (2011–2012) had died. This
was to allow for the possibility that deaths in the later cohorts
were underrepresented because of the differential time for
deaths to be captured both through routine programme systems
and through linkage to the hospital information system and the
Africa Centre Demographic Information System. We have pre-
viously shown by linking programme data to demographic
surveillance data that 40% of adults lost to follow-up in the
ﬁrst 3 months of ART had died.21 All analyses were conducted
using STATA 11.2 (StataCorp, College Station, TX).
Ethics Statement
Ethical approval was granted by the Biomedical Research
Ethics Committee of the University of KwaZulu-Natal and the
Health Research Committee of the KwaZulu-Natal Department
of Health for the retrospective analysis of data from the Hlabisa
HIV Treatment and Care Programme (references BE066/07 and
HRKM012/07).
RESULTS
Temporal Changes in CD4+ Cell Count at
Initiation of ART
A total of 19,747 adults initiated ART during the period
under analysis, among them 19,080 (96.6%) had a baseline
CD4+ cell count recorded. Annual enrollment increased from
280 adults in 2004–2005 to 4199 in 2011–2012. Median age
was 34 years (IQR: 28–42); 12,906 (67.6%) were female and,
of those, 10.7% (1383/12,906) initiated ART while pregnant.
Overall median baseline CD4+ cell count was 139 cells per
microliter (IQR: 71–198) and was higher for females than
males (151 vs. 111 cells per microliter, P , 0.001).
There was no signiﬁcant change in baseline CD4+ cell
count over the ﬁrst 6 years (110–134 cells per microliter) and
only a modest increase to 145 cells per microliter in 2010–
2011 after the initial extension of eligibility to CD4+ cell count
,350 cells per microliter for pregnant women and TB patients
(Table 1). In the last time period (2011–2012), there was a sig-
niﬁcant increase and the median CD4+ cell count of 199 cells
per microliter (IQR: 110–280) was more than 50 cells per
microliter higher than for any other time period. This was
accompanied by a substantial decline in the proportion with
CD4+ cell count ,50 cells per microliter, reaching a low of
11.5% [95% conﬁdence interval (CI): 10.6 to 12.5] in 2011–
2012. The same temporal pattern was observed when males
and nonpregnant females were studied separately (Table 1; Fig.
1). The proportionate rise in median CD4+ cell count between
2010–2011 and 2011–2012 was similar for these 2 groups,
although the differences between the 2 groups remained con-
stant, with males having lower median CD4+ cell count and
higher proportion with CD4+ cell count ,50 cells per micro-
liter in all time periods. For pregnant females, a rise in median
CD4+ cell count was observed over the last 2 time periods
(2010–2011 and 2011–2012), consistent with the earlier imple-
mentation of the CD4+ cell count threshold of 350 cells per
microliter for pregnant women in April 2010. There was a low
proportion of pregnant females with CD4+ cell count,50 cells
per microliter across all time periods.
Temporal Changes in CD4+ Cell Count at First
Presentation for Care
A total of 41,300 adults had their ﬁrst CD4+ cell count
measurement between August 2007 and July 2012 (Table 2).
Overall median CD4+ cell count at ﬁrst presentation was 273
cells per microliter (IQR: 136–444). There was limited change
in the ﬁrst 4 time periods but a signiﬁcant rise in 2011–2012
(median: 317 cells per microliter; IQR: 170–487). This was
accompanied in the last time period by a signiﬁcant decline
in the proportion that presented with CD4+ cell count,50 cells
per microliter and a rise in the proportion that presented with
CD4+ cell count .350 cells per microliter.
Early Mortality
A total of 19,080 individuals were included in mortality
analysis with 4506 person-years of follow-up (median: 86
days). There were 875 deaths (4.6%) in the ﬁrst 3 months of
ART giving a crude early mortality rate of 19.4 per 100 person-
years (95% CI: 18.2 to 20.7). Six hundred forty-one individuals
(3.4%) were lost to follow-up and 170 (0.9%) transferred out of
the programme within 3 months. The deaths in the ﬁrst 3
months represented 59.6% (875/1469) of all deaths observed in
the ﬁrst year of ART. There was no substantial change in early
mortality until the last period where there was a large decline in
mortality rate: from 21.3 per 100 person-years (95% CI: 18.3 to
24.8) in 2010–2011 to 9.0 per 100 person-years (95% CI: 7.3
to 11.0) in 2011–2012 (Fig. 2A). This pattern was consistent
for both males and nonpregnant females (Figs. 2B,C); there
were too few early deaths in the pregnant female group (n = 9)
for temporal trends to be explored.
In competing risks regression, after adjustment for sex,
age, baseline CD4+ cell count, and concurrent TB, the time
period of ART initiation was strongly associated with mortality
in the ﬁrst 3 months of ART: subhazard ratio (SHR) 0.54 (95%
CI: 0.41 to 0.71) for 2011–2012 compared with the reference
time period of 2008–2009 (Table 3). CD4+ cell count ,50
cells per microliter was strongly associated with early mortality
(SHR: 4.25; 95% CI: 3.23 to 5.60). Compared with nonpreg-
nant females, males had higher early mortality (SHR: 1.48;
95% CI: 1.28 to 1.70), whereas pregnant females had substan-
tially lower early mortality (SHR: 0.23; 95% CI: 0.12 to 0.45).
When the analysis was restricted to individuals with
CD4+ cell count ,50 cells per microliter and #200 cells per
microliter, the substantial reduction in early mortality rate was
still observed for the 2011–2012 cohort (see Table, Supple-
mental Digital Content 1, http://links.lww.com/QAI/A433).
The proportion of each annual cohort lost to follow-up
within the ﬁrst 3 months increased over time: 0.4% (95%
CI: 0 to 1.1) for 2004–2005, 0.6% (95% CI: 0.1 to 1.0) for
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2005–2006, 1.6% (95% CI: 1.0 to 2.3) for 2006–2007, 1.2%
(95% CI: 0.8 to 1.6) for 2007–2008, 2.7% (95% CI: 2.2 to 3.
3) for 2008–2009, 3.9% (95% CI: 3.2 to 4.6) for 2009–2010,
4.4% (95% CI: 3.7 to 5.1) for 2010–2011, and 5.4% (95%
CI: 4.7 to 6.1) for 2011–2012. In sensitivity analyses,
assuming deaths in 20% and 40% of those lost to follow-
up from 2011 to 2012, estimates of corrected early mortality
for that period were 13.5 per 100 person-years (95% CI: 11.
4 to 16.0) and 18.0 per 100 person-years (95% CI: 15.6 to
20.9), respectively (see Figure, Supplemental Digital
Content 2, http://links.lww.com/QAI/A433).
DISCUSSION
In this observational study, we found evidence not only
of earlier presentation for ART but also a substantial
reduction in early mortality on ART subsequent to the change
in CD4+ cell count eligibility criteria that took effect in South
Africa in August 2011. Median CD4+ cell count at ART
initiation remained higher and mortality remained lower for
women during all time periods, consistent with the data from
this region.22,23 However, it is encouraging that the increase in
CD4+ cell count and reduction in early mortality for those
who initiated ART in the last time period (2011–2012) were
consistent for both the nonpregnant females and males. Preg-
nant women only represented about 7% of all adults who
initiated ART and there were very few deaths in this group;
so there was limited statistical power to observe any temporal
trends. These data provide further encouragement at a time
when substantial reductions in population-level mortality
have been documented in this community and more broadly
in South Africa.24–27
We have previously shown that during the ﬁrst phase of
rapid programme scale-up, there was no signiﬁcant change in
CD4+ cell count at ART initiation.4 It seems that after the ﬁrst
policy change in 2010 to recommend ART at ,350 cells per
microliter for TB patients and pregnant females, there
was minimal change in the overall median CD4+ cell count
TABLE 1. Trends in Baseline CD4+ Cell Count Overall and by Sex Categories (Males, Nonpregnant Females, and Pregnant
Females)
2004–2005 2005–2006 2006–2007 2007–2008
Overall
Number of individuals 280 907 1408 2754
Median (IQR), cells/mL 111 (58–163) 122 (61–178) 116 (52–176) 113 (58–172)
% CD4+ cell count ,50 cells/mL (95% CI) 22.1 (17.7–27.4) 20.6 (18.1–23.4) 24.1 (21.9–26.4) 21.3 (19.8–22.9)
Males
Number of individuals 88 294 458 874
Median (IQR), cells/mL 77 (40–146) 108 (49–169) 95 (37–164) 90 (42–152)
% CD4+ cell count ,50 cells/mL (95% CI) 30.7 (22.0–41.0) 25.5 (20.9–30.8) 31.9 (27.8–36.3) 29.1 (26.2–32.2)
Females (nonpregnant)
Number of individuals 190 601 934 1727
Median (IQR), cells/mL 122 (68–169) 127 (65–182) 126 (62–182) 126 (65–177)
% CD4+ cell count ,50 cells/mL (95% CI) 18.4 (13.6–24.5) 18.5 (15.6–21.8) 20.3 (17.9–23.0) 18.5 (16.7–20.4)
Females (pregnant)
Number of individuals 2 12 16 153
Median (IQR), cells/mL 88 (63–113) 138 (109–190) 142 (59–186) 140 (87–190)
% CD4+ cell count ,50 cells/mL (95% CI) — 8.3 (0–24.7) 18.8 (0–38.5) 8.5 (4.1–13.0)
2008–2009 2009–2010 2010–2011 2011–2012 Overall
Overall
Number of individuals 3079 3159 3294 4199 19,080
Median (IQR), cells/mL 123 (61–175) 134 (72–187) 145 (76–201) 199 (110–280) 139 (71–198)
% CD4+ cell count ,50 cells/mL (95% CI) 20.2 (18.9–21.7) 17.4 (16.1–18.8) 16.2 (15.0–17.5) 11.5 (10.6–12.5) 17.6 (17.1–18.2)
Males
Number of individuals 1099 1050 982 1329 6174
Median (IQR), cells/mL 98 (45–161) 111 (51–171) 113 (49–176) 160 (72–250) 111 (49–179)
% CD4+ cell count ,50 cells/mL (95% CI) 27.2 (24.7–29.9) 24.9 (22.3–27.6) 25.6 (23.0–28.4) 18.6 (16.6–20.8) 25.3 (24.2–26.4)
Females (nonpregnant)
Number of individuals 1825 1845 1859 2542 11,523
Median (IQR), cells/mL 133 (70–179) 143 (80–189) 149 (80–197) 212 (125–289) 147 (79–200)
% CD4+ cell count ,50 cells/mL (95% CI) 17.5 (15.8–19.3) 14.7 (13.2–16.4) 14.5 (13.0–16.2) 9.0 (7.9–10.1) 15.1 (14.5–15.8)
Females (pregnant)
Number of individuals 155 264 453 328 1383
Median (IQR), cells/mL 152 (109–191) 174 (105–246) 216 (145–280) 241 (163–294) 190 (123–265)
% CD4+ cell count ,50 cells/mL (95% CI) 3.2 (0.4–6.0) 6.8 (3.8–9.9) 2.9 (1.3–4.4) 2.7(1.0–4.5) 4.5 (3.5–5.7)
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at ART initiation, yet after the expansion to ,350 cells per
microliter for all, there has been a deﬁnite increase. This sug-
gests that, although antenatal care and TB services remain
important entry points to HIV treatment, the contribution from
these groups alone was too small to see a broader impact of the
expanded eligibility criteria. The increase in overall median
CD4+ cell count between 2010–2011 and 2011–2012 was 54
cells per microliter, which corresponds approximately to 6
months earlier in terms of disease progression according to
our previous data.17 The relationship between mortality risk
and time period was maintained after adjustment for baseline
CD4+ cell count, consistent with the fact that CD4+ cell count
does not fully predict mortality,28 and that other factors associ-
ated with earlier presentation, such as the absence of opportu-
nistic infection, may have contributed to the mortality decline.
It is noteworthy that in the last time period, there was a decline
in the absolute number and the proportion of people who ini-
tiated ART with CD4+ cell count ,50 cells per microliter, as
this remains the factor most strongly associated with early mor-
tality, with a 4-fold increased risk of early mortality compared
with CD4+ cell count of 201–350 cells per microliter.
These observations provide robust evidence that the
reduction in early mortality has occurred since the policy
change to recommend earlier initiation of ART, although
a direct causal association cannot be inferred from these
observational data. In common with data from other large
programmes in South Africa, early mortality did not change
in the ﬁrst few years of programme scale-up.29–31 Only in the
last time period (2011–2012), there was a real decline in early
mortality. There have been no speciﬁc interventions or pro-
grammatic changes that could easily explain the decline in
early mortality. There is no formal package of care for indi-
viduals before eligibility for ART and retention in this group
is suboptimal.32 We have previously shown that TB is the
most common cause of early mortality on ART and that
prevalent TB at time of ART initiation is associated with
almost double the risk of mortality on ART, in line with other
studies in the region.32–34 In this analysis, there was no inde-
pendent association between TB and early mortality, although
the statistical power to observe an association might have
been affected by the lower risk of TB disease at higher
CD4+ cell counts.35 The implementation of isoniazid preven-
tive therapy was scaled up from early 2010, yet provision
remains patchy in this programme. It could be that improved
integration of ART with TB treatment has contributed to the
reduction in mortality, in line with ﬁndings from clinical
trials.36,37 Alternatively, although there was no speciﬁc pro-
grammatic change, it could be related to clinic systems becom-
ing more efﬁcient over time, increased use of nurse-initiated
ART, or by the shorter time needed for pre-ART work-up for
people with higher CD4+ cell counts. Finally, given the change
in the ﬁrst-line antiretroviral regimen in 2010 from a stavudine-
FIGURE 1. CD4+ cell count at initiation of ART by
time period and sex (nonpregnant females and
males). Upper and lower margins of the box rep-
resent the 25th and 75th percentiles, respectively,
with the horizontal line representing the median;
whiskers represent fifth and 95th percentiles.
TABLE 2. Temporal Changes in CD4+ Cell Count at First Presentation for Care
2007–2008 2008–2009 2009–2010 2010–2011 2011–2012 Overall
Number of ﬁrst CD4+ cell count
tests
9662 8655 7584 6860 8539 41,300
CD4+ cell count, median (IQR),
cells/mL
253 (128–420) 263 (129–438) 267 (127–446) 263 (132–431) 317 (170–487) 273 (136–444)
CD4+ cell count, cells/mL,
% (95% CI)
,50 10.4 (9.8–11.0) 10.9 (10.2–11.6) 10.4 (9.7–11.1) 10.7 (10.0–11.5) 7.8 (7.3–8.4) 10.0 (9.8–10.3)
50–200 29.5 (28.6–30.5) 27.8 (26.8–28.7) 27.7 (26.7–28.7) 27.7 (26.7–28.8) 21.8 (21.0–22.7) 26.9 (26.5–27.4)
201–350 25.8 (25.0–26.7) 24.8 (23.9–25.7) 25.0 (24.0–26.0) 25.8 (24.8–26.9) 26.4 (25.4–27.3) 25.6 (25.2–26.0)
.350 34.2 (33.2–35.1) 36.6 (35.6–37.6) 36.9 (35.8–37.9) 35.7 (34.6–36.8) 44.0 (42.9–45.0) 37.5 (37.0–37.9)
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FIGURE 2. Mortality in the first 3 months of ART in
all adults (N = 19,080) (A), males (N = 6174) (B),
nonpregnant females (N = 11,523) (C).
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based to tenofovir-based regimen, we cannot discount that this
may have accounted for some of the mortality change,
although against this would be the fact that the majority of
fatal adverse events related to stavudine (eg, lactic acidosis)
occur after the ﬁrst 3 months.38
Earlier presentation for treatment may be not only
indirectly related to the policy changes but also to improved
HIV testing coverage in the community, facilitated by the
nationwide HIV counseling and testing (HCT) campaign and
local initiatives to scale up home- and community-based HIV
counseling and testing.39 This is supported by the fact that the
CD4+ cell count at enrollment in the programme also shifted
substantially in the period since August 2011, to the extent
that almost half of the adults who enrolled into care between
August 2011 and July 2012 had a CD4+ cell count.350 cells
per microliter. Policy changes alone have no impact unless the
health system is able to provide the services and individuals are
able and willing to access those services. Our data are, there-
fore, important to show not only that people are accessing
treatment earlier but that, so far, the health system has been
able to cope with the increasing patient load. Not all countries
are following WHO recommendations with regard to ART
eligibility criteria, and these data should contribute to the evi-
dence base around the impact of earlier access to ART.40
As early LTF increased over time, mortality may have
been underestimated, especially in the last time period because
of the shorter time for deaths to be captured. The correction of
mortality for LTF is complicated in our programme as, before
analysis, some correction occurs routinely through linkage to
the hospital information system and demographic surveillance
system. Under a worst-case but unrealistic scenario, where the
proportion of LTF in the last time period attributable to
mortality was 40%, the estimated mortality decline was much
less marked, but under a more realistic assumption of 20%, the
decline remained signiﬁcant.
The strengths of this analysis relate to the simplicity
and quality of the data from a well-characterized treatment
programme. Only 6% of adults who initiated ART had
a missing baseline CD4+ cell count (considerably lower than
the 25% reported from a multicohort collaboration in South
Africa41), thus minimizing potential bias. Nevertheless, inter-
pretation of the ﬁndings should be subject to some caution.
We were unable within this analysis to explore outcomes for
those people who, while eligible, did not initiate ART. We
cannot, therefore, exclude the possibility that unmeasured
variations over time in mortality for those who did not access
ART could offset the mortality decline observed for those
who access ART, although the consistent decline in popula-
tion-level mortality would argue against this.27 Data regarding
in-hospital deaths from the Hospital Information System were
only available from January 2011 and in-hospital deaths dur-
ing earlier time periods might have been missed if they had
not been reported through the routine systems of the HIV
treatment and care programme. However, this would be
expected to bias the ﬁndings away from the null hypothesis
and therefore would strengthen our ﬁndings. Although the
ﬁndings should be broadly generalizable to public-sector pro-
grammes in South Africa, it is possible that not only extra
ﬁnancial support to the programme but also the research and
community engagement activities in the area might inﬂuence
access to and uptake of treatment and replication of this anal-
ysis should be performed with other programmes.
In conclusion, we have demonstrated that in this rural
area, since the policy shift to recommend ART for all adults
with CD4+ cell count ,350 cells per microliter, there has
been a signiﬁcant increase in the median baseline CD4+ cell
count and a signiﬁcant reduction in mortality within the ﬁrst 3
months of ART. These ﬁndings provide support for national
and international ART policies and highlight the importance
of earlier ART initiation for achieving reductions in HIV-
related mortality.
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